ATE402696T1 - Heterozyklische amidderivate, die glycogen phosphorylase inhibierende aktivität besitzen - Google Patents
Heterozyklische amidderivate, die glycogen phosphorylase inhibierende aktivität besitzenInfo
- Publication number
- ATE402696T1 ATE402696T1 AT04743648T AT04743648T ATE402696T1 AT E402696 T1 ATE402696 T1 AT E402696T1 AT 04743648 T AT04743648 T AT 04743648T AT 04743648 T AT04743648 T AT 04743648T AT E402696 T1 ATE402696 T1 AT E402696T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- alkyl
- glycogen phosphorylase
- sub
- inhibiting activity
- Prior art date
Links
- 102000007390 Glycogen Phosphorylase Human genes 0.000 title abstract 3
- 108010046163 Glycogen Phosphorylase Proteins 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 150000001408 amides Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- -1 nitro, cyano, hydroxy, fluoromethyl Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000005549 heteroarylene group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0318463.7A GB0318463D0 (en) | 2003-08-07 | 2003-08-07 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE402696T1 true ATE402696T1 (de) | 2008-08-15 |
Family
ID=27839758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04743648T ATE402696T1 (de) | 2003-08-07 | 2004-08-04 | Heterozyklische amidderivate, die glycogen phosphorylase inhibierende aktivität besitzen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20080064691A1 (de) |
| EP (1) | EP1658069B1 (de) |
| JP (1) | JP2007501779A (de) |
| AT (1) | ATE402696T1 (de) |
| DE (1) | DE602004015474D1 (de) |
| ES (1) | ES2309537T3 (de) |
| GB (1) | GB0318463D0 (de) |
| WO (1) | WO2005013981A1 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0222912D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| GB0222909D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| EP1848721A1 (de) * | 2005-02-05 | 2007-10-31 | AstraZeneca AB | Chemische verbindungen |
| US8053603B2 (en) | 2006-01-06 | 2011-11-08 | Sunovion Pharmaceuticals Inc. | Tetralone-based monoamine reuptake inhibitors |
| BRPI0706365A2 (pt) | 2006-01-06 | 2011-03-22 | Sepracor Inc | Cicloalquilaminas como inibidores da recaptação de monoamina |
| EP2816024B8 (de) | 2006-03-31 | 2018-04-04 | Sunovion Pharmaceuticals Inc. | Chirale Amine |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| US7902252B2 (en) | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| CA2688493C (en) | 2007-05-31 | 2016-04-19 | Sepracor Inc. | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors |
| US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| CA2826649C (en) | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| RU2015106909A (ru) | 2012-08-02 | 2016-09-27 | Мерк Шарп И Доум Корп. | Антидиабетические трициклические соединения |
| BR112015019836A2 (pt) | 2013-02-22 | 2017-07-18 | Merck Sharp & Dohme | composto, composição farmacêutica, e, uso de um composto |
| EP2970119B1 (de) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Neuartige indolderivate als antidiabetika |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3706810A (en) * | 1970-09-15 | 1972-12-19 | American Cyanamid Co | N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides |
| US4692522A (en) * | 1985-04-01 | 1987-09-08 | Merck & Co., Inc. | Benzofused lactams useful as cholecystokinin antagonists |
| US4668769A (en) * | 1985-08-02 | 1987-05-26 | Hoover Dennis J | Oxa- and azahomocyclostatine polypeptides |
| US4599198A (en) * | 1985-08-02 | 1986-07-08 | Pfizer Inc. | Intermediates in polypeptide synthesis |
| US4720503A (en) * | 1985-08-02 | 1988-01-19 | Merck & Co., Inc. | N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors |
| FR2601368B1 (fr) * | 1986-07-08 | 1989-04-07 | Synthelabo | Derives de nitrofuranne, leur preparation et leur application en therapeutique. |
| DE3629545A1 (de) * | 1986-08-30 | 1988-03-10 | Bayer Ag | Dihydropyridinverbindungen, verfahren zu ihrer herstellung und ihre verwendung |
| US4751231A (en) * | 1987-09-16 | 1988-06-14 | Merck & Co., Inc. | Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents |
| US5863903A (en) * | 1994-03-09 | 1999-01-26 | Novo Nordisk A/S | Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes |
| US5998463A (en) * | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
| EP1136071A3 (de) * | 2000-03-22 | 2003-03-26 | Pfizer Products Inc. | Verwendung von Glykogen-Phosphorylase-Hemmern |
| GB0021831D0 (en) * | 2000-09-06 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| GB0205170D0 (en) * | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| US7057046B2 (en) * | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
| US20040082641A1 (en) * | 2002-10-28 | 2004-04-29 | Rytved Klaus Asger | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases |
| US7098235B2 (en) * | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
| EP1633709A1 (de) * | 2003-04-30 | 2006-03-15 | Pfizer Products Inc. | Verbindungen zur verwendung als anti-diabetika |
-
2003
- 2003-08-07 GB GBGB0318463.7A patent/GB0318463D0/en not_active Ceased
-
2004
- 2004-08-04 JP JP2006522397A patent/JP2007501779A/ja not_active Withdrawn
- 2004-08-04 AT AT04743648T patent/ATE402696T1/de not_active IP Right Cessation
- 2004-08-04 WO PCT/GB2004/003345 patent/WO2005013981A1/en not_active Ceased
- 2004-08-04 EP EP04743648A patent/EP1658069B1/de not_active Expired - Lifetime
- 2004-08-04 US US10/566,063 patent/US20080064691A1/en not_active Abandoned
- 2004-08-04 ES ES04743648T patent/ES2309537T3/es not_active Expired - Lifetime
- 2004-08-04 DE DE602004015474T patent/DE602004015474D1/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HK1090288A1 (en) | 2006-12-22 |
| JP2007501779A (ja) | 2007-02-01 |
| DE602004015474D1 (de) | 2008-09-11 |
| WO2005013981A1 (en) | 2005-02-17 |
| EP1658069B1 (de) | 2008-07-30 |
| GB0318463D0 (en) | 2003-09-10 |
| EP1658069A1 (de) | 2006-05-24 |
| US20080064691A1 (en) | 2008-03-13 |
| ES2309537T3 (es) | 2008-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE402696T1 (de) | Heterozyklische amidderivate, die glycogen phosphorylase inhibierende aktivität besitzen | |
| ES2308441T3 (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos. | |
| CA2684037C (en) | Compounds with anti-cancer activity | |
| PT1024138E (pt) | Derivados de pirazole | |
| Shaykoon et al. | Design, synthesis and antitrypanosomal activity of heteroaryl-based 1, 2, 4-triazole and 1, 3, 4-oxadiazole derivatives | |
| ATE413876T1 (de) | Indolamid-derivate, die glycogen phosphorylase inhibierende aktivität besitzen | |
| CA2042922A1 (en) | Anti-tumour compounds | |
| CA2526026C (en) | Furazanobenzimidazoles | |
| TW200732329A (en) | Aryl-isoxazolo-4-yl-oxadiazole derivatives | |
| BR0308145A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
| JPWO1998046594A1 (ja) | ピラゾール誘導体およびそれを含有するｃｏｘ阻害剤 | |
| CN100390156C (zh) | 新抗菌化合物、其制备方法和含有它们的药物组合物 | |
| NO309603B1 (no) | Fremgangsmåte til fremstilling av substituerte dibenz[b,f][1,4]-oksazepin-11(10H)oner | |
| JP2007505888A (ja) | オキシトシン拮抗薬としての置換トリアゾール誘導体 | |
| Munikrishnappa et al. | Design, synthesis, and biological evaluation of novel bromo-pyrimidine analogues as tyrosine kinase inhibitors | |
| AU680496B2 (en) | Novel bisoxadiazolidine derivative | |
| US5760063A (en) | Arylhydrazone derivatives useful as antibacterial agents | |
| BG107908A (bg) | Инхибитори на фарнезилтрансфераза | |
| Yonetoku et al. | Novel potent and selective Ca2+ release-activated Ca2+ (CRAC) channel inhibitors. Part 3: synthesis and CRAC channel inhibitory activity of 4′-[(trifluoromethyl) pyrazol-1-yl] carboxanilides | |
| EP0737672B1 (de) | Verfahren zur Herstellung von Triazinderivate | |
| ES2308442T3 (es) | Compuestos de pirazolamina para el tratamiento de trastornos neurodegenerativos. | |
| TW200510304A (en) | Chemical compounds | |
| WO2003074485A3 (en) | Indole-amide derivatives and their use as glycogen phosphorylase inhibitors | |
| PL171273B1 (pl) | Sposób wytwarzania nowych pochodnych tiadiazynonów PL | |
| US6166033A (en) | 2-carbonylthiazole derivatives and use of the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |